The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010–2018

References

• Demmer RT, Zuk AM, Rosenbaum M, et al. Prevalence of diagnosed and undiagnosed type 2 diabetes mellitus among US adolescents: results from the continuous NHANES, 1999–2010. Am J Epidemiol. 2013;178(7):1106–1113.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the american college of physicians. Ann Intern Med. 2012;156(3):218–231.
   PubMed Web of Science ®Google Scholar
• Garg A, Kumar A. Risk and benefit profile of dulaglutide in established therapeutic indication. Curr Drug Saf. 2018;13(3):165–170.
   PubMed Web of Science ®Google Scholar
• Singh M, Sharma R, Kumar A. Safety of SGLT2 inhibitors in patients with diabetes mellitus. Curr Drug Saf. 2019;14(2):87–93.
   PubMed Web of Science ®Google Scholar
• Hong D, Si L, Jiang M, et al. Cost effectiveness of Sodium-Glucose cotransporter-2 (SGLT2) inhibitors, Glucagon-Like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review. Pharmacoeconomics. 2019;37(6):777–818.
   PubMed Web of Science ®Google Scholar
• Tong L, Adler S. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Postgrad Med. 2018;130(4):381–393.
   PubMed Web of Science ®Google Scholar
• Patti AM, Rizvi AA, Giglio RV, et al. Impact of Glucose-Lowering medications on cardiovascular and metabolic risk in type 2 diabetes. J Clin Med. 2020;9(4):912.
   Web of Science ®Google Scholar
• IBM. [cited 2021 Aug 18]. Available from: https://www.ibm.com/products/marketscan-research-databases.
   Google Scholar
• Shiroiwa T, Sung Y-K, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19(4):422–437.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334.
   PubMed Web of Science ®Google Scholar
• Roehrig C. The impact of prescription drug rebates on health plans and consumers. Published online 2018. 37; [cited 2021 Aug 18]. Available from: https://altarum.org/sites/default/files/Altarum-Prescription-Drug-Rebate-Report_April-2018.pdf.
   Google Scholar
• Johnson N, Mills C, Kridgen M. America’s Health Insurance Plans. Published online 2018. [cited 2021 Aug 18]. Available from: https://www.ahip.org/wp-content/uploads/2018/07/AHIP-Part-D-Rebates-20180716.pdf.
   Google Scholar
• Zhou X, Shrestha SS, Shao H, Zhang P. Factors contributing to the rising national cost of Glucose-Lowering medicines for diabetes during 2005-2007 and 2015-2017. Diabetes Care. 2020;43(10):2396–2402.
   PubMed Web of Science ®Google Scholar
• Desai NC, Pandit UP, Dodiya A. Thiazolidinedione compounds: a patent review (2010 – present). Published online 2014. 10.
   Google Scholar
• Rajkumar SV. The high cost of insulin in the United States: an urgent call to action. Mayo Clin Proc. 2020;95(1):22–28.
   PubMed Web of Science ®Google Scholar
• Eleftheriadou I, Grigoropoulou P, Liberopoulos E, et al. Update on cardiovascular effects of older and newer anti-diabetic medications. Curr Med Chem. 2018;25(13):1549–1566.
   PubMed Web of Science ®Google Scholar
• Palanisamy S, Yien E, Shi L, et al. Systematic review of efficacy and safety of newer antidiabetic drugs approved from 2013 to 2017 in controlling HbA1c in diabetes patients. Pharmacy. 2018;6(3):57.
   Web of Science ®Google Scholar
• Gu S. Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis. Published online 2020. 21.
   Google Scholar
• Rowley WR, Bezold C, Arikan Y, et al. Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag. 2017;20(1):6–12.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–928.
   PubMed Web of Science ®Google Scholar
• Chakravarty A, Rastogi M, Dhankhar P, et al. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the U.S. setting. J Med Econ. 2018;21(5):497–509.
   PubMed Web of Science ®Google Scholar
• Dempsey M, Mocarski M, Langer J, et al. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the U.S. J Med Econ. 2018;21(11):1110–1118.
   PubMed Web of Science ®Google Scholar
• Ektare VU, Lopez JMS, Martin SC, et al. Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus. Am J Manag Care. 2014;20(10 Suppl):S204–S215.
   PubMed Web of Science ®Google Scholar
• Giugliano D, Ceriello A, De Nicola L, et al. Primary versus secondary cardiorenal prevention in type 2 diabetes: which newer anti-hyperglycaemic drug matters? Diabetes Obes Metab. 2020;22(2):149–157.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Braunwald E. Clinical benefit of cardiorenal effects of Sodium-Glucose cotransporter 2 Inhibitors: JACC State-of-the-art review. J Am Coll Cardiol. 2020;75(4):435–447.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Alfonso-Cristancho R, Conner C, et al. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovasc Diabetol. 2009;8:12.
   PubMed Web of Science ®Google Scholar
• Lee WC, Conner C, Hammer M. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the U.S. Curr Med Res Opin. 2011;27(5):897–906.
   PubMed Web of Science ®Google Scholar
• Minshall ME, Oglesby AK, Wintle ME, et al. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health. 2008;11(1):22–33.
   PubMed Web of Science ®Google Scholar
• Bergenheim K, Williams SA, Bergeson JG, et al. US cost-effectiveness of saxagliptin in type 2 diabetes mellitus. Am J Pharm Benef. 2012;4(1):20–28.
   Google Scholar
• Sinha A, Rajan M, Hoerger T, et al. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes Care. 2010;33(4):695–700.
   PubMed Web of Science ®Google Scholar
• Samyshkin Y, Guillermin A-L, Best JH, et al. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the U.S. J Med Econ. 2012;15(Suppl 2):6–13.
   PubMedGoogle Scholar
• Hunt B, Mocarski M, Valentine WJ, et al. IDegLira versus insulin glargine U100: a long-term cost-effectiveness analysis in the US Setting. Diabetes Ther. 2017;8(3):531–544.
   PubMed Web of Science ®Google Scholar
• Hunt B, Mocarski M, Valentine WJ, et al. Evaluation of the Short-Term Cost-Effectiveness of IDegLira versus continued up-Titration of insulin glargine U100 in patients with type 2 diabetes in the USA. Adv Ther. 2017;34(4):954–965.
   PubMed Web of Science ®Google Scholar
• Gaebler JA, Soto-Campos G, Alperin P, et al. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc Health Risk Manag. 2012;8:255–264.
   PubMedGoogle Scholar